Biosimilar Biological Products: An Introduction

Understand background and definitions of biologic and biosimilar drugs and new drug applications (NDAs) and biologics license applications (BLAs). Summarize biosimilar pathways to market and application contents. Learn about the types of meetings available to interact with FDA. Examine interchangeability standards and conditions of use.

William Holtz, Principal, Leavitt Partners, LLC

This session was recorded as part of FDLI’s Introduction to Biological Products, Including Vaccines, Biosimilars, Cell and Gene Therapies, and Other Advanced Therapies Course in October 2022.

Get Access

$99

+$100 for nonmembers

Buy Now

Internet Explorer and Microsoft Edge are not supported by the checkout process.

Please use Chrome, Firefox, or Safari. If you are unable to use these browsers, please contact us at 202-371-1420 or [email protected] and we will assist you.

Virtual Learning FAQ

When will I receive my session?

On-demand webinar content is sent via email as soon as we are able to process and verify your order. This usually occurs within 1 business day.

Is my computer/mobile device compatible?

On-demand content can be played back on most devices.

Is CLE credit available?

CLE credit is not currently available for pre-recorded sessions.

Related Content

Hannah Brown2023-05-08T09:14:48-04:00
Recent Rulings on Mifepristone Access: Implications for FDA and Stakeholders

daniel.zinn2023-03-30T14:19:01-04:00
The Regulation of Cosmetics: An Introduction

Kiana Walker2023-03-30T14:10:03-04:00
Overview of U.S. Food Law and Regulation: An Introduction

daniel.zinn2023-03-22T14:54:53-04:00
Overview of Biological Products Law and FDA’s Regulatory Processes

Hannah Brown2023-01-27T12:30:57-05:00
Implementation of the Inflation Reduction Act: Healthcare Reform and Implications for the Pharmaceutical Industry

Hannah Brown2023-01-04T13:57:54-05:00
Fundamentals of FDA Regulation of Cosmetics

Kiana Walker2022-12-16T13:05:47-05:00
International Issues for Medical Device Manufacturers: An Introduction

Kiana Walker2022-12-16T12:57:42-05:00
An Introduction to the Regulation of Promotion and Advertising for Medical Devices

Kiana Walker2022-12-16T12:48:31-05:00
FDA Authorities and Processes for the Enforcement, Compliance, and Inspection of Medical Devices

Kiana Walker2022-12-16T12:40:47-05:00
Regulatory Requirements for Medical Device Manufacturing and Quality System (QS) Regulation: An Introduction

Kiana Walker2022-12-16T12:36:12-05:00
Post Marketing Issues for Medical Devices: An Introduction

Kiana Walker2022-12-16T12:24:27-05:00
An Introduction to Coverage, Coding, and Payment of Medical Devices – Collaboration Between FDA and the Centers for Medicare and Medicaid Services (CMS)

Kiana Walker2022-12-16T12:20:02-05:00
Medical Device Premarket Approval Applications (PMA); Humanitarian Device Exemption (HDE) and Breakthrough Devices: An Introduction

Kiana Walker2022-12-16T12:14:08-05:00
An Introduction to the Medical Device Approval Process: Premarket Notification 510(k) and De Novo Requests

Kiana Walker2022-12-16T12:14:28-05:00
Medical Device Clinical Investigations: An Introduction

Hannah Brown2022-12-16T11:57:39-05:00
Regulation of Digital Health Products: An Introduction

Hannah Brown2022-12-16T11:52:22-05:00
An Introduction to the Regulation of Combination Products for Medical Devices

Kiana Walker2022-12-16T11:46:38-05:00
Overview of Medical Device Law and Regulation

Kiana Walker2022-12-15T13:38:22-05:00
An Introduction to Drug Enforcement: FDA Enforcement Authorities, Tools, Violations and Initiatives

Kiana Walker2022-12-15T13:31:46-05:00
Regulation of Drug Marketing: An Introduction

Kiana Walker2022-12-15T13:32:41-05:00
Regulation of Drug Manufacturing: An Introduction

Kiana Walker2022-12-15T13:16:38-05:00
Regulation of Over-the-Counter (OTC) Drugs: An Introduction

Hannah Brown2022-12-15T12:48:26-05:00
The Regulation of Biologics and Biosimilars: An Introduction

Kiana Walker2022-12-15T12:34:13-05:00
Post Approval Requirements for Drugs: An Introduction to Safety Reporting and Post-Approval Changes

Kiana Walker2022-12-15T12:29:17-05:00
An Introduction to the Abbreviated NDA (ANDA), 505(b)(2) Applications, and Patent and Exclusivity Issues

Kiana Walker2022-12-15T12:25:25-05:00
The New Drug Approval Process: NDA Submission and Review

Kiana Walker2022-12-15T11:59:49-05:00
The New Drug Approval Process: New Drug Research and Development

Kiana Walker2022-12-15T11:50:53-05:00
The New Drug Approval Process: Basic Concepts

Kiana Walker2022-12-15T11:46:42-05:00
Origins and Overview of Drug Law Regulation: An Introduction

daniel.zinn2022-11-02T10:01:16-04:00
An Introduction to Violations, Enforcement, and International Issues in Biologics and Biosimilars

daniel.zinn2022-11-02T09:56:13-04:00
The Regulation of Biological Product Marketing: An Introduction

daniel.zinn2022-11-02T10:04:53-04:00
The Regulation of Biological Product Manufacturing: An Introduction

daniel.zinn2022-11-02T10:05:58-04:00
Post-Approval Pharmacovigilance of Biological Products: An Introduction

Kiana Walker2022-11-02T10:07:04-04:00
Biologics and Biosimilars: An Introduction

Hannah Brown2022-11-01T15:53:35-04:00
Biological Product Approval, Vaccines, Emergency Use Authorization: An Introduction

Hannah Brown2022-11-03T14:08:38-04:00
FDLI Book Launch—How FDA Really Works: Insights from the Experts

Hannah Brown2022-11-01T15:51:29-04:00
Introduction to Human Cellular and Tissue Based Products (HCT/P), Cell Therapy and Gene Therapy

daniel.zinn2022-11-01T15:49:41-04:00
Regulation of Biological Product/Drug Development: An Introduction

daniel.zinn2022-11-01T15:52:54-04:00
Introduction to FDA Review and Approval of Biological Products

Kiana Walker2022-10-21T11:41:42-04:00
Food and Drug Administration (FDA) Inspections and Enforcement: Tobacco and Nicotine Product Manufacturers and Retailers

Kiana Walker2022-10-21T11:44:07-04:00
Tobacco and Nicotine Product Compliance

Kiana Walker2022-10-21T11:29:41-04:00
The Public Heath Standard for Tobacco and Nicotine Products

Kiana Walker2022-10-21T11:23:47-04:00
Pathways to Market for Tobacco and Nicotine Products

Kiana Walker2022-10-21T11:18:04-04:00
United States Tobacco and Nicotine Product Regulation: The Family Smoking Prevention and Tobacco Control Act (TCA) and the Deeming Regulation

Kiana Walker2022-10-21T10:44:26-04:00
Case Studies/Hypotheticals for an Introduction to Medical Product Advertising and Promotion

Kiana Walker2022-10-21T10:35:39-04:00
An Introduction to Other Agencies and Considerations Involved in Medical Product Advertising and Promotion

Kiana Walker2022-10-21T10:27:29-04:00
An Introduction to Dissemination of Information about Unapproved Uses for Medical Product Advertising and Promotion

Kiana Walker2022-10-21T10:20:55-04:00
An Introduction to Applicable FDA Offices, Essential Principles, & Key Definitions for Medical Product Advertising and Promotion

Hannah Brown2023-01-04T14:07:20-05:00
Supply Chain Mayhem: Industry Impacts and What Can be Done

daniel.zinn2022-10-03T14:11:28-04:00
Food and Dietary Supplement Imports and International Issues: An Introduction

daniel.zinn2022-10-03T13:39:40-04:00
FDA Inspection and Enforcement Authority for Food and Dietary Supplement Manufacturers

daniel.zinn2022-10-03T13:30:04-04:00
Food Advertising: An Introduction to the Federal Trade Commission and Private Rights of Action

Kiana Walker2022-10-03T13:20:54-04:00
Food Labeling: An Introduction to Nutrient Content, Health, and Other Claims

Kiana Walker2022-10-03T13:16:09-04:00
Food Labeling: An Introduction to General Requirements (Including Meat and Poultry)

daniel.zinn2022-10-03T13:00:22-04:00
The Regulation of Dietary Supplements: An Introduction

Kiana Walker2022-10-03T12:53:56-04:00
Foods Derived from Biotechnology – the USDA/FDA Conundrum

daniel.zinn2022-10-03T12:50:17-04:00
An Introduction to U.S. Department of Agriculture Labeling, Inspection and Ingredient Approval Requirements

Kiana Walker2022-10-03T12:33:25-04:00
Food Safety: Current Good Manufacturing Practices and Related Requirements; Unintended Components/Contaminants of Food

Kiana Walker2022-10-03T12:25:11-04:00
Food Safety: An Introduction to Ingredient Preclearance/Intentional Components of Food

Hannah Brown2022-09-28T14:47:09-04:00
Updates and Developments in Drug Compounding

Hannah Brown2023-01-27T12:31:25-05:00
Essentials of Post-Inspection Actions: From FDA Notices to Criminal Prosecution

Hannah Brown2022-09-28T14:51:46-04:00
Essentials of Inspection Readiness for Medical Products

Hannah Brown2022-09-28T14:52:12-04:00
Essentials of FDA, DOJ, FTC Enforcement Authorities

Hannah Brown2022-09-28T14:56:47-04:00
You Can’t Outsource Responsibility: Managing Quality in a Contract Manufacturing Partnership

Hannah Brown2022-09-28T14:58:43-04:00
Over-the-Counter Drugs Monograph Reform – How’s it Going?

Kiana Walker2022-05-05T14:31:41-04:00
FDA’s COVID-19 Activities

Tina Chang2022-09-28T15:02:51-04:00
FDA’s Expedited Programs: Understanding Which Program Best Suits Your Product

Hannah Brown2022-04-13T12:18:44-04:00
The Promise and Problem of Blockchain for Medical Products: What Lawyers Need to Know

Kiana Walker2022-07-08T12:07:10-04:00
Navigating the Complexities of Combination Product Regulation

Kiana Walker2021-11-24T09:53:29-05:00
Medical Device Clinical Investigations: An Introduction to Sponsor Responsibilities and Compliance Issues

Kiana Walker2021-11-24T09:43:50-05:00
Medical Device Manufacturer Requirements: An Introduction to Registration and Listing of Establishments

Kiana Walker2022-07-08T12:07:32-04:00
FDA and Centers for Medicare and Medicaid Services: Regulatory Considerations for Communicating and Contracting for Value

Kiana Walker2022-07-08T12:07:47-04:00
Best Practices for Drug Recalls

Kiana Walker2021-07-26T08:56:41-04:00
The Essentials of Food Science

Kiana Walker2021-11-03T14:16:02-04:00
Machine Learning for Regulatory Attorneys and English Majors

Kiana Walker2022-07-08T12:08:17-04:00
The Essentials of Tobacco and Nicotine Product Research

Kiana Walker2021-07-15T08:39:58-04:00
The Essentials of Statistics for Medical Products Lawyers

Kiana Walker2021-06-17T08:46:40-04:00
The Essentials of Clinical Trial Science

Kiana Walker2021-05-27T08:50:48-04:00
How Does FDA’s Recent Guidance on Remote Interactive Evaluations Change the Inspections Landscape?

Kiana Walker2022-07-08T12:08:32-04:00
Biologic and Biosimilar Litigation and IP Rights

Kiana Walker2022-07-08T12:08:46-04:00
The Impact of COVID-19 on the In Vitro Diagnostic Industry

Kiana Walker2022-07-08T12:09:02-04:00
Biosimilars: Regulatory Challenges and Barriers to Entry

Kiana Walker2021-02-16T14:12:53-05:00
Introduction to Vaccine Regulation

Kiana Walker2021-02-16T14:11:06-05:00
Vaccine Development and Clinical Trials

Kiana Walker2021-02-16T14:10:52-05:00
Vaccine Pathways to Market

Kiana Walker2021-02-16T14:12:11-05:00
Vaccine Manufacturing, Scaling, Supply Chain, and Administration Issues

Kiana Walker2021-02-16T14:10:28-05:00
Vaccine Enforcement and Litigation

Kiana Walker2020-11-12T11:11:29-05:00
An Introduction to Managing Promotional Issues for Medical Products in a Virtual Setting

Kiana Walker2020-12-11T08:59:47-05:00
Intro to COVID-19: Drug Issues

Kiana Walker2020-12-11T08:59:16-05:00
Intro to COVID-19: Diagnostics and Laboratory Testing

Kiana Walker2020-12-11T08:58:46-05:00
Intro to COVID-19: Combating Fraudulent Products

Kiana Walker2020-12-11T08:58:12-05:00
Intro to COVID-19: Enforcement Action Guidelines, Legal Liabilities and Concerns

Kiana Walker2020-12-11T08:55:12-05:00
Intro to COVID-19: Personal Protection Equipment (PPE)

Kiana Walker2020-12-11T08:53:55-05:00
Intro to COVID-19: Ventilators and 3D Printed Devices

Kiana Walker2020-12-11T08:56:36-05:00
Intro to COVID-19: Public Readiness and Emergency Preparedness Act (PREP ACT)

Kiana Walker2020-12-11T08:56:45-05:00
Intro to COVID-19: Defining Emergency Use Authorization (EUA) Authorities

Kiana Walker2021-01-19T14:31:40-05:00
State of FDA Medical Product Manufacturer Inspections During and After COVID-19

Kiana Walker2022-07-08T12:12:11-04:00
Restarting Clinical Trials in the Wake of COVID-19

Kiana Walker2022-07-08T12:14:15-04:00
COVID-19 and Beyond: Development and Implementation of Recovery Action Plans for Medical Product Manufacturers

Kiana Walker2020-05-19T10:54:47-04:00
The Long-Awaited Biologics Transition Date Has Come: What Now?

Kiana Walker2020-05-19T13:36:36-04:00
FDA’s Recent COVID-19 Guidances Facilitating Expanded Access to Certain Medical Products

Kiana Walker2020-05-18T16:44:51-04:00
FDA-Related Congressional Committees: Jurisdiction, Focus, and Roles

Kiana Walker2020-05-19T13:39:15-04:00
Nicotine: What it Is, What it Does, and How to Effectively Communicate this Information to the Public

Kiana Walker2020-05-19T13:40:05-04:00
The CREATES Act Has Passed: What Does It Mean for the Generics Industry?

Kiana Walker2020-05-19T13:41:22-04:00
A Practical Guide to Bringing a Dietary Supplement to Market

Kiana Walker2020-05-19T13:42:30-04:00
Reducing Anti-Kickback Risks Associated with Medical Products

LauraHaak2020-05-19T13:52:51-04:00
Introduction to the Regulation of Cannabis-Derived Products

LauraHaak2020-05-19T13:04:13-04:00
Introduction to Product Liability Regarding FDA-Regulated Products

admin2020-05-19T13:07:31-04:00
Due Diligence: Ensuring Your Deal Doesn’t Collapse Due to Regulatory, Clinical, Quality, or Data Integrity Issues

admin2020-05-19T14:01:46-04:00
Patient Assistance Programs: Recent Enforcement and Best Practices

admin2020-05-19T13:36:03-04:00
From Approval to Coverage – FDA and CMS Jurisdictional Lines

admin2020-05-19T14:05:16-04:00
Drug Pricing for the Food and Drug Community

admin2020-05-19T14:15:41-04:00
Organic Chemistry for the Food and Drug Community

admin2020-05-19T14:44:31-04:00
DEA Law for the Food and Drug Community

admin2020-05-19T15:02:17-04:00
Real World Evidence: Data Requirements, Utilization, and Presentation

admin2020-05-19T15:15:05-04:00
FDA, USDA, and EPA: Inter-Agency Overlap and Jurisdictional Boundaries

admin2020-05-19T15:16:31-04:00
PDUFA and BsUFA Reauthorization: Key Changes Affecting Industry and Patients

admin2020-05-19T15:40:28-04:00
Recent FDA Guidance Documents on Manufacturer Communications about Medical Products

admin2020-05-19T15:46:52-04:00
21st Century Cures Act